8-K Announcements
6Material company update
Mar 12, 2026·SEC
Material company update
Dec 29, 2025·SEC
Material company update
Nov 13, 2025·SEC
Vaxart, Inc.(VXRT)Earnings, Financials & Key Ratios
VXRT•NASDAQ
$0.75
$179M mkt cap·10.6× P/E·Price updated May 6, 2026
AboutVaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.Show more
- Revenue$237M+726.7%
- EBITDA$18M+131.5%
- Net Income$16M+124.4%
- EPS (Diluted)0.07+150.0%
- EBITDA Margin7.62%+103.8%
- Operating Margin7.62%+103.3%
- Net Margin6.88%+103.0%
- ROE22.26%+119.4%
- ROIC27.12%+129.1%
- Debt/Equity0.10-74.1%
VXRT Key Insights
Vaxart, Inc. (VXRT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓Momentum leader: RS Rating 93 (top 7%)
- ✓Strong 5Y sales CAGR of 125.8%
- ✓Share count reduced 52.7% through buybacks
- ✓Efficient asset utilization: 1.3x turnover
✗Weaknesses
- ✗Low quality earnings: Net income not backed by cash flow
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
VXRT Price & Volume
Vaxart, Inc. (VXRT) stock price & volume — 10-year historical chart
Loading chart...
VXRT Growth Metrics
Vaxart, Inc. (VXRT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years38.25%
5 Years125.76%
3 Years1204%
TTM726.68%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM124.39%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM131.2%
Return on Capital
10 Years-61.57%
5 Years-51.35%
3 Years-49.71%
Last Year15.06%
VXRT Recent Earnings
Vaxart, Inc. (VXRT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
Mar 12, 2026EPS
$0.24
Est $0.08
+400.0%
Revenue
$104M
Est $36M
+190.0%
Q4 2025
Nov 13, 2025EPS
$0.04
Est $0.07
+42.9%
Revenue
$72M
Est $36M
+101.4%
Q3 2025
Aug 13, 2025EPS
$0.07
Est $0.09
+22.2%
Revenue
$40M
Est $2M
+1705.9%
Q2 2025
May 13, 2025EPS
$0.07
Est $0.07
+0.0%
Revenue
$21M
Est $3M
+632.5%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 12, 2026 | $0.24vs $0.08+400.0% | $104Mvs $36M+190.0% |
| Q4 2025 | Nov 13, 2025 | $0.04vs $0.07+42.9% | $72Mvs $36M+101.4% |
| Q3 2025 | Aug 13, 2025 | $0.07vs $0.09+22.2% | $40Mvs $2M+1705.9% |
| Q2 2025 | May 13, 2025 | $0.07vs $0.07+0.0% | $21Mvs $3M+632.5% |
Based on last 12 quarters of dataView full earnings history →
VXRT Peer Comparison
Vaxart, Inc. (VXRT) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVAX | 1.53B | 9.36 | 3.69 | 64.69% | -14.73% | |||
 IBRX | 8.25B | 8.38 | -13.52 | 22.71% | -422.28% | |||
 CODX | 1.8M | 1.61 | -0.05 | -84.1% | -75.34% | -125.46% | 0.06 | |
 OCGN | 492.54M | 1.46 | -6.33 | 8.83% | -15.37% | -26.26% | ||
 DYAI | 27.51M | 0.76 | -3.80 | 20.58% | -279.56% | -281.83% | 2.05 | |
 MRNA | 19.35B | 48.79 | -6.72 | -39.23% | -143.55% | -36.73% | 0.22 | |
 PFE | 150.77B | 26.51 | 19.49 | -1.65% | 11.83% | 8.34% | 0.78 | |
 SNY | 105.71B | 43.77 | 18.37 | 5.49% | 16.72% | 10.78% | 0.30 |
Compare VXRT vs Peers
Vaxart, Inc. (VXRT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VXRT Income Statement
Vaxart, Inc. (VXRT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 5.84M | 4.16M | 9.86M | 4.05M | 892K | 107K | 7.38M | 28.7M | 237.26M |
| Revenue Growth % | -34.39% | -28.77% | 137.12% | -58.97% | -77.95% | -88% | 6796.26% | 288.94% | 726.68% |
| Cost of Goods Sold | 12.36M | 17.27M | 0 | 19.86M | 48.75M | 0 | 4.5M | 0 | 0 |
| COGS % of Revenue | 211.59% | 415.36% | - | 490.93% | 5465.13% | - | 60.98% | - | - |
| Gross Profit | -6.52M▲ 0% | -13.12M▼ 101.3% | 9.86M▲ 175.2% | -15.82M▼ 260.4% | -47.86M▼ 202.6% | 107K▲ 100.2% | 2.88M▲ 2590.7% | 28.7M▲ 896.9% | 0▼ 100.0% |
| Gross Margin % | -111.59% | -315.36% | 100% | -390.93% | -5365.13% | 100% | 39.02% | 100% | - |
| Gross Profit Growth % | 25.39% | -101.29% | 175.19% | -260.38% | -202.57% | 100.22% | 2590.65% | 896.87% | -100% |
| Operating Expenses | 83K | 23.96M | 25.65M | 14.35M | 24.89M | 114.69M | 86.23M | 94.99M | 219.18M |
| OpEx % of Revenue | 1.42% | 576% | 260.06% | 354.75% | 2790.92% | 107190.65% | 1168.53% | 330.99% | 92.38% |
| Selling, General & Admin | 2.6M | 6.68M | 6.19M | 15.2M | 21.89M | 29.39M | 22.58M | 20.78M | 17.61M |
| SG&A % of Revenue | 44.51% | 160.64% | 62.74% | 375.73% | 2454.04% | 27463.55% | 306.06% | 72.4% | 7.42% |
| Research & Development | 12.36M | 17.27M | 14.54M | 19.86M | 48.75M | 81.05M | 68.14M | 74.21M | 201.58M |
| R&D % of Revenue | 211.59% | 415.36% | 147.43% | 490.93% | 5465.13% | 75751.4% | 923.46% | 258.58% | 84.96% |
| Other Operating Expenses | 0 | 0 | 4.92M | -20.71M | -45.74M | 4.25M | -4.5M | 0 | 0 |
| Operating Income | -9.12M▲ 0% | -21.76M▼ 138.7% | -15.79M▲ 27.4% | -30.17M▼ 91.1% | -72.75M▼ 141.1% | -114.59M▼ 57.5% | -83.35M▲ 27.3% | -66.29M▲ 20.5% | 18.07M▲ 127.3% |
| Operating Margin % | -156.11% | -523.11% | -160.06% | -745.67% | -8156.05% | -107090.65% | -1129.52% | -230.99% | 7.62% |
| Operating Income Growth % | 66.85% | -138.68% | 27.45% | -91.13% | -141.14% | -57.5% | 27.26% | 20.46% | 127.26% |
| EBITDA | -8.73M | -18.55M | -12.19M | -28.32M | -70.32M | -108.78M | -74.72M | -57.44M | 18.07M |
| EBITDA Margin % | -149.6% | -446.09% | -123.6% | -700.05% | -7883.41% | -101665.42% | -1012.64% | -200.15% | 7.62% |
| EBITDA Growth % | 68.12% | -112.4% | 34.3% | -132.37% | -148.27% | -54.7% | 31.31% | 23.13% | 131.46% |
| D&A (Non-Cash Add-back) | 380K | 3.2M | 3.6M | 1.85M | 2.43M | 5.8M | 8.62M | 8.85M | 0 |
| EBIT | -9.12M | -15.22M | -15.77M | -30.11M | -68.88M | -106.39M | -80.76M | -63.72M | 0 |
| Net Interest Income | 0 | -2.62M | -2.24M | -1.8M | -1.4M | -58K | 1.21M | -426K | 0 |
| Interest Income | 2.98M | 58K | 149K | 75K | 81K | 1.25M | 2.65M | 2.54M | 0 |
| Interest Expense | 0 | 2.68M | 2.39M | 1.87M | 1.48M | 1.3M | 1.45M | 2.97M | 0 |
| Other Income/Expense | -467K | 3.86M | -2.37M | -1.81M | 2.39M | 6.9M | 1.14M | -395K | -1.27M |
| Pretax Income | -9.58M▲ 0% | -17.9M▼ 86.8% | -18.16M▼ 1.4% | -31.98M▼ 76.2% | -70.36M▼ 120.0% | -107.69M▼ 53.1% | -82.2M▲ 23.7% | -66.69M▲ 18.9% | 16.8M▲ 125.2% |
| Pretax Margin % | -164.1% | -430.34% | -184.09% | -790.46% | -7888.23% | -100645.79% | -1114.03% | -232.36% | 7.08% |
| Income Tax | 0 | 109K | 490K | 238K | 107K | 67K | 261K | 260K | 476K |
| Effective Tax Rate % | 0% | -0.61% | -2.7% | -0.74% | -0.15% | -0.06% | -0.32% | -0.39% | 2.83% |
| Net Income | -12.46M▲ 0% | -18.01M▼ 44.5% | -18.64M▼ 3.5% | -32.22M▼ 72.8% | -70.47M▼ 118.7% | -107.76M▼ 52.9% | -82.47M▲ 23.5% | -66.95M▲ 18.8% | 16.33M▲ 124.4% |
| Net Margin % | -213.39% | -432.96% | -189.06% | -796.34% | -7900.22% | -100708.41% | -1117.56% | -233.27% | 6.88% |
| Net Income Growth % | 57.62% | -44.52% | -3.54% | -72.81% | -118.72% | -52.91% | 23.47% | 18.82% | 124.39% |
| Net Income (Continuing) | -9.58M | -18.01M | -18.64M | -32.22M | -70.47M | -107.76M | -82.47M | -66.95M | 16.33M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.28▲ 0% | -0.29▼ 0.7% | -0.09▲ 69.8% | -0.07▲ 23.1% | -0.14▼ 111.8% | -0.22▼ 57.1% | -0.17▲ 22.7% | -0.14▲ 17.6% | 0.07▲ 150.0% |
| EPS Growth % | 66.19% | -0.71% | 69.82% | 23.14% | -111.8% | -57.14% | 22.73% | 17.65% | 150% |
| EPS (Basic) | -0.33 | -0.29 | -0.09 | -0.07 | -0.14 | -0.22 | -0.17 | -0.14 | 0.07 |
| Diluted Shares Outstanding | 44.07M | 63.16M | 215.7M | 487.26M | 487.26M | 487.26M | 487.26M | 487.26M | 230.35M |
| Basic Shares Outstanding | 37.84M | 63.16M | 215.7M | 487.26M | 487.26M | 487.26M | 487.26M | 487.26M | 230.27M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
VXRT Balance Sheet
Vaxart, Inc. (VXRT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 3.75M | 14.64M | 17.6M | 128.53M | 169.17M | 99.45M | 45.54M | 68.26M | 115.15M |
| Cash & Short-Term Investments | 2.99M | 11.46M | 13.53M | 126.87M | 166.49M | 93.72M | 39.71M | 51.72M | 63.81M |
| Cash Only | 1.57M | 11.46M | 13.53M | 126.87M | 143.75M | 44.01M | 34.76M | 25.23M | 53.81M |
| Short-Term Investments | 1.42M | 0 | 0 | 0 | 22.74M | 49.7M | 4.96M | 26.49M | 9.99M |
| Accounts Receivable | 630K | 1.8M | 3.62M | 334K | 71K | 20K | 3.01M | 11.97M | 51.34M |
| Days Sales Outstanding | 39.38 | 157.62 | 133.94 | 30.13 | 29.05 | 68.22 | 148.79 | 152.22 | 78.99 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 1.34M | 0 | 1.33M | 0 | 2M | 333K | 318K | 0 |
| Total Non-Current Assets | 770K | 20.58M | 19.43M | 24.05M | 52M | 54.4M | 46.29M | 98.13M | 33.18M |
| Property, Plant & Equipment | 730K | 1.07M | 2.2M | 8.32M | 19.77M | 41.3M | 36.57M | 29.11M | 25.85M |
| Fixed Asset Turnover | 8.00x | 3.90x | 4.48x | 0.49x | 0.05x | 0.00x | 0.20x | 0.99x | 9.18x |
| Goodwill | 0 | 0 | 0 | 0 | 4.51M | 4.51M | 4.51M | 4.51M | 4.51M |
| Intangible Assets | 40K | 19.41M | 17.09M | 15.36M | 10.62M | 5.02M | 4.29M | 3.56M | 2.83M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 16.21M | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 103K | 141K | 372K | 890K | 3.57M | 926K | 60.95M | 0 |
| Total Assets | 4.52M▲ 0% | 35.23M▲ 678.8% | 37.03M▲ 5.1% | 152.58M▲ 312.0% | 221.17M▲ 45.0% | 153.85M▼ 30.4% | 91.83M▼ 40.3% | 166.39M▲ 81.2% | 186.08M▲ 11.8% |
| Asset Turnover | 1.29x | 0.12x | 0.27x | 0.03x | 0.00x | 0.00x | 0.08x | 0.17x | 1.28x |
| Asset Growth % | -88.72% | 678.84% | 5.12% | 312.03% | 44.95% | -30.44% | -40.31% | 81.19% | 11.83% |
| Total Current Liabilities | 4.52M | 7.47M | 9.17M | 11.76M | 10.78M | 17.92M | 13.72M | 90.88M | 21.56M |
| Accounts Payable | 1.39M | 962K | 852K | 2.13M | 3.87M | 5.51M | 1.58M | 6.96M | 21.5M |
| Days Payables Outstanding | 41.06 | 20.33 | - | 39.2 | 28.99 | - | 128.48 | - | - |
| Short-Term Debt | 1.53M | 1.67M | 0 | 4.83M | 836K | 95K | 3.8M | 4.06M | 2.98M |
| Deferred Revenue (Current) | 0 | 1.52M | 4.57M | 0 | 0 | 0 | 0 | 0 | 68K |
| Other Current Liabilities | 88K | 3.78M | 2.01M | 3.18M | 1 | 2M | 0 | 65.4M | 18.52M |
| Current Ratio | 0.83x | 1.96x | 1.92x | 10.93x | 15.69x | 5.55x | 3.32x | 0.75x | 5.34x |
| Quick Ratio | 0.83x | 1.96x | 1.92x | 10.93x | 15.69x | 5.55x | 3.32x | 0.75x | 5.34x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 38.72M | 16.51M | 14.91M | 17.41M | 22.85M | 25.33M | 20.3M | 16.59M | 76.72M |
| Long-Term Debt | 38.72M | 1.94M | 0 | 12.15M | 10.69M | 5.62M | 2.62M | 1.7M | 6.01M |
| Capital Lease Obligations | 0 | 0 | 1.47M | 5.16M | 12M | 19.48M | 17.39M | 14.45M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 14.57M | 13.43M | 109K | 171K | 231K | 293K | 439K | 76.72M |
| Total Liabilities | 43.24M | 23.99M | 24.08M | 29.18M | 33.64M | 43.25M | 34.02M | 107.46M | 98.28M |
| Total Debt | 40.25M | 3.61M | 2.31M | 22.14M | 24.53M | 27.42M | 26.51M | 23.28M | 8.98M |
| Net Debt | 38.68M | -7.84M | -11.21M | -104.73M | -119.22M | -16.59M | -8.24M | -1.95M | -44.83M |
| Debt / Equity | - | 0.32x | 0.18x | 0.18x | 0.13x | 0.25x | 0.46x | 0.40x | 0.10x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | 0.50x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | -2.48x |
| Interest Coverage | - | -8.12x | -6.61x | -16.10x | -49.16x | -87.81x | -57.60x | -22.33x | - |
| Total Equity | -38.72M▲ 0% | 11.24M▲ 129.0% | 12.95M▲ 15.3% | 123.4M▲ 852.8% | 187.53M▲ 52.0% | 110.6M▼ 41.0% | 57.8M▼ 47.7% | 58.92M▲ 1.9% | 87.8M▲ 49.0% |
| Equity Growth % | -307.07% | 129.02% | 15.25% | 852.78% | 51.97% | -41.02% | -47.73% | 1.94% | 49% |
| Book Value per Share | -0.88 | 0.18 | 0.06 | 0.25 | 0.38 | 0.23 | 0.12 | 0.12 | 0.38 |
| Total Shareholders' Equity | -38.72M | 11.24M | 12.95M | 123.4M | 187.53M | 110.6M | 57.8M | 58.92M | 87.8M |
| Common Stock | 0 | 714K | 5K | 11K | 13K | 13K | 15K | 23K | 24K |
| Retained Earnings | -79.98M | -97.99M | -116.66M | -148.88M | -219.35M | -327.11M | -409.57M | -476.52M | -460.19M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | -366K | -350K | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | -74K | -299K | -1K | 4K | -3K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VXRT Cash Flow Statement
Vaxart, Inc. (VXRT) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -10.04M | -14.55M | -13.09M | -23.75M | -59.83M | -94.78M | -70.45M | -44.76M | 7.71M |
| Operating CF Margin % | -171.95% | -349.8% | -132.73% | -587% | -6707.62% | -88578.5% | -954.78% | -155.97% | 3.25% |
| Operating CF Growth % | 66.53% | -44.9% | 10.02% | -81.44% | -151.92% | -58.41% | 25.67% | 36.46% | 117.23% |
| Net Income | -9.58M | -18.01M | -18.64M | -32.22M | -70.47M | -107.76M | -82.47M | -66.95M | 16.33M |
| Depreciation & Amortization | 380K | 3.2M | 3.6M | 2.71M | 4.21M | 5.8M | 8.62M | 8.85M | 8.58M |
| Stock-Based Compensation | 477K | 539K | 627K | 4.36M | 8.87M | 13.59M | 14.13M | 11.5M | 8.31M |
| Deferred Taxes | 0 | 1.72M | 1.37M | 0 | 3.09M | 4.09M | 0 | 0 | 0 |
| Other Non-Cash Items | -2.25M | -4.45M | -1.32M | -1.4M | -3.41M | -5.81M | 106K | -1.43M | -25.51M |
| Working Capital Changes | 935K | 2.45M | 1.28M | 2.81M | -2.12M | -4.7M | -10.85M | 3.26M | 0 |
| Change in Receivables | 960K | 13.5M | -1.82M | 3.29M | 263K | 51K | -2.99M | -2.75M | -8.8M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | -7.11M | 0 | 0 | 0 |
| Change in Payables | 0 | -3.78M | -62K | 1.21M | 1.63M | 357K | -2.44M | 5.27M | 14.64M |
| Cash from Investing | 3.18M | 26.21M | -850K | -1.22M | -49.1M | -20.41M | 43.95M | -21.32M | 16.63M |
| Capital Expenditures | -117K | -707K | -850K | -1.22M | -5.16M | -9.6M | -1.87M | -554K | -145K |
| CapEx % of Revenue | 2% | 17% | 8.62% | 30.23% | 578.14% | 8972.9% | 25.36% | 1.93% | 0.06% |
| Acquisitions | 0 | 25.5M | 0 | 3K | -4.83M | 10.81M | 120K | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 3.3M | 1.42M | 0 | 0 | 0 | -10.81M | 0 | -9.95M | -4.2M |
| Cash from Financing | 24K | -1.73M | 15.96M | 138.31M | 125.8M | 17.46M | 15.24M | 56.56M | 4.24M |
| Debt Issued (Net) | 0 | -1.74M | -3.8M | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 24K | 13K | 1.41M | 27.2M | 3.59M | 225K | 213K | -214K | 4.24M |
| Net Change in Cash | -6.83M▲ 0% | 9.94M▲ 245.4% | 2.02M▼ 79.7% | 113.34M▲ 5511.1% | 16.88M▼ 85.1% | -97.73M▼ 679.2% | -11.26M▲ 88.5% | -9.53M▲ 15.4% | 28.59M▲ 400.1% |
| Free Cash Flow | -10.16M▲ 0% | -15.26M▼ 50.2% | -13.94M▲ 8.6% | -24.97M▼ 79.1% | -64.99M▼ 160.2% | -104.38M▼ 60.6% | -72.32M▲ 30.7% | -45.32M▲ 37.3% | 7.57M▲ 116.7% |
| FCF Margin % | -173.95% | -366.79% | -141.35% | -617.23% | -7285.76% | -97551.4% | -980.13% | -157.9% | 3.19% |
| FCF Growth % | 66.73% | -50.19% | 8.62% | -79.15% | -160.24% | -60.61% | 30.71% | 37.34% | 116.7% |
| FCF per Share | -0.23 | -0.24 | -0.06 | -0.05 | -0.13 | -0.21 | -0.15 | -0.09 | 0.03 |
| FCF Conversion (FCF/Net Income) | 0.81x | 0.81x | 0.70x | 0.74x | 0.85x | 0.88x | 0.85x | 0.67x | 0.47x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VXRT Key Ratios
Vaxart, Inc. (VXRT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -90.6% | - | -160.23% | -154.15% | -47.26% | -45.33% | -72.29% | -97.94% | -114.71% | 22.26% |
| Return on Invested Capital (ROIC) | -1586.54% | -1087.71% | -974.15% | -461.37% | -221.73% | -125.45% | -105.89% | -87.08% | -93.33% | 27.12% |
| Gross Margin | -98.13% | -111.59% | -315.36% | 100% | -390.93% | -5365.13% | 100% | 39.02% | 100% | - |
| Net Margin | -330.34% | -213.39% | -432.96% | -189.06% | -796.34% | -7900.22% | -100708.41% | -1117.56% | -233.27% | 6.88% |
| Debt / Equity | 0.02x | - | 0.32x | 0.18x | 0.18x | 0.13x | 0.25x | 0.46x | 0.40x | 0.10x |
| Interest Coverage | -15.28x | - | -8.12x | -6.61x | -16.10x | -49.16x | -87.81x | -57.60x | -22.33x | - |
| FCF Conversion | 1.02x | 0.81x | 0.81x | 0.70x | 0.74x | 0.85x | 0.88x | 0.85x | 0.67x | 0.47x |
| Revenue Growth | -4.3% | -34.39% | -28.77% | 137.12% | -58.97% | -77.95% | -88% | 6796.26% | 288.94% | 726.68% |
VXRT SEC Filings & Documents
Vaxart, Inc. (VXRT) SEC filings — annual & quarterly reports (10-K, 10-Q)
VXRT Frequently Asked Questions
Vaxart, Inc. (VXRT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Vaxart, Inc. (VXRT) reported $237.3M in revenue for fiscal year 2025. This represents a 1% decrease from $239.9M in 1996.
Vaxart, Inc. (VXRT) grew revenue by 726.7% over the past year. This is strong growth.
Yes, Vaxart, Inc. (VXRT) is profitable, generating $16.3M in net income for fiscal year 2025 (6.9% net margin).
Dividend & Returns
Vaxart, Inc. (VXRT) has a return on equity (ROE) of 22.3%. This is excellent, indicating efficient use of shareholder capital.
Vaxart, Inc. (VXRT) generated $7.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More VXRT
Vaxart, Inc. (VXRT) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates